Individuals who have only partial or short responses to skin-directed therapies, or more advanced stages of disease, may benefit from systemic therapy. Learn more about available systemic therapies.
Extracorporeal photopheresis (ECP) was the first therapy approved by the Food and Drug Administration (FDA) specifically for the treatment of cutaneous T-cell lymphoma. ECP may be an effective treatment for CTCL that has not responded to other types of therapy.
Living with cutaneous lymphoma and understanding the diversity of the treatment options available can be overwhelming. The good news is that there are many treatment options available today.
